Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CareDx, Inc    CDNA

CAREDX, INC

(CDNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

CareDx Leadership at ASTS Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2020 | 07:01am EDT

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, maintains a leading presence at the American Society of Transplant Surgeons Winter Symposium January 9-12, 2020 in Miami, Florida.

CareDx is prominently featured in a lunch symposium on Friday, January 10, 2020 at ASTS. The symposium titled “Changing the Care Paradigm with AlloSure” features five leaders in the transplant field:

  • David Axelrod, MD, University of Iowa
  • Joseph Scalea, MD, University of Maryland
  • Stan Jordan, MD, Cedars-Sinai
  • Robert Redfield, MD, University of Wisconsin
  • Ty Dunn, MD, University of Pennsylvania

“CareDx’s commitment to continued innovation in transplantation is highlighted at ASTS with the data. New data being presented at ASTS demonstrates AlloSure’s ability to differentiate patients with ambiguous rejection,” said Velma Scantlebury, MD, Christiana Health. “The focus on AlloSure and KidneyCare for patient management is a key discussion for us in the transplant community.”

“The CareDx theme for 2020 is Transplant Proud, exemplified in our relationships with the transplant community and the presence we bring to the American Society of Transplant Surgeons meeting,” said Peter Maag, CEO of CareDx.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com 

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CAREDX, INC
03/20REPEAT - NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted Af..
GL
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
AQ
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
GL
03/17CAREDX LAUNCHES REMOTRAC : Home-Based Monitoring of Transplant Patients
GL
03/12CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney..
GL
03/05CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-..
GL
02/28CareDx to Participate in Upcoming Investor Conferences
GL
02/28CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/27CAREDX : 4Q Earnings Snapshot
AQ
02/27CAREDX, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 167 M
EBIT 2020 -21,6 M
Net income 2020 -20,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -51,7x
P/E ratio 2021 937x
Capi. / Sales2020 5,60x
Capi. / Sales2021 4,32x
Capitalization 937 M
Chart CAREDX, INC
Duration : Period :
CareDx, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAREDX, INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 45,00  $
Last Close Price 21,85  $
Spread / Highest target 170%
Spread / Average Target 106%
Spread / Lowest Target 60,2%
EPS Revisions
Managers
NameTitle
Peter K. Maag Chairman & Chief Executive Officer
Reginald Seeto President & Chief Business Officer
Paul Ciccolella Senior Vice President-Global Operations
Michael Bell Chief Financial & Principal Accounting Officer
Robert N. Woodward Vice President-Research & Development
Sector and Competitors